ABSTRACT
Objective:This study was conducted to evaluate and discuss the curative effect and toxicity of gemcitabine, navel-bine, and therarubicin (GNT) regimen for patients with refractory or relapsed T-cell lymphoma (TCL). Methods:A total of 69 patients with refractory or relapsed TCL treated with GNT were enrolled. The treatment protocol was set as follows:800 mg/m2 gemcitabine ad-ministered at 1 and 8 d;25 mg/m2 navelbine administered at 1 d;and 20 mg/m2 therarubicin administered at 1 d. This protocol was re-peated every three weeks. The median cycle was 4 (range:2 to 6). Results:The overall response rate was 65.2%and the achieved com-plete remission was 29.0%. Hematology toxicities were the main adverse reactions observed in all of the patients. The incidence rates of grades 1 and 2 toxicity in leukopenia or neutropenia, anemia, and thrombocytopenia were 50.7%, 33.3%, and 26.1%, respectively. Grades 3 and 4 treatment-associated toxicities were detected in 23.1%of the responding patients. One-, three-, and five-year estimated overall survival (OS) of the whole cohort were 71.7%, 47.3%, and 32.4%, respectively. The median OS was 36 months. Conclusion:GNT was effective and suitable for patients with refractory or relapsed TCL.
ABSTRACT
Objective To observe the efficacy and adverse reaction of NP and GX regimens in the treatment of the anthracycline-and-taxane-resistant advanced breast cancer.Methods Totally 75 patients with advanced breast cancer were divided into two groups,and received NP or GX regimen.NP group (n =40):NVB 25 mg/m2,day 1,day 8,iv.drip; DDP 25 mg/m2,day 1-3,iv.drip.GX group (n =35):GEM 1000 mg/m2 day 1,day 8,iv.drip; XEL 2500 mg/m2,day 1-14,bid po.Every 21 days was a cycle.The efficacy and adverse reaction were evaluated after two cycles.Results The overall response rates in the NP and GX group were 42.5 ％ (17/40) and 40.0 ％ (14/35).The median TTP of two group were 7 and 6.5 months.The MST was 15.8 and 15.0 months in the NP and GX group.The 1-and 2-year survival rates were 60.0 ％,32.5 ％ and 57.1％,31.4 ％.The increase ratio of Karnofsky were 50.0 ％ and 42.9 ％.There were not significant difference between the two groups in terms of their treatment response (P ＞ 0.05).The main adverse reactions in the two group were myelosuppression,gastrointestinal reaction and phlebitis.Hand-foot syndrome in GX was significantly higher than that in NP group,Gastrointestinal reactions in NP was significantly higher than that in GX group (P ＜ 0.05).Conclusion NP and GX regimens are effective for patients with metastatic breast cancer,their adverse reactions are tolerable,so they can be regarded as a ltermate regimens for anthracyclines and taxanes resistant patients with metastatic breast cancer.
ABSTRACT
Objective To compare the therapeutic effects of two different intervention methods in the treatment of Navelbine leakage.Methods 40 cases with Navelbine leakage were collected and randomly divided into the control group and the observation group in equal number.Local block therapy in earlier period was used in the control group,and non-local block therapy was adopted in the observation group.Then the therapeutic effects of the two methods were compared.Results The differences of effect between the observation group and the control group were significant.Conclusions Local medicine injection in earlier period,wet compress and microwave physiotherapy after 24 hours is more effective than the local block in earlier period in the treatment of Navelbine leakage.It may shorten the time of pain and detumesccnce obviously,so it is worth popularizing clinically.
ABSTRACT
Objectives: To evaluate the efficacy, toxicity and side effects of CAP (cytoxan, adriamycin, cisplatin), NP(navelbine, cisplatin), GP(gemcitabine, cisplatin) in the treatment of patients with non small cell Lung cancer(NSCLC). Methods:146 patients with NSCLC diagnosed by pathology or cytology were treated with CAP, GP or GP regimen. Results:The overall response rate of the three groups (CAP, NP, GP)were 33.33%, 46.43% and 47.92% respectively. The major toxicity and side effects was bone marrow inhibition and the gastrointestinal reaction. Grade Ⅲ-Ⅳ side effects of CAP group were significant higher than the others. Conclusions:The regimen of navelbine and cisplatin or gemcitabine and cisplatin was more effective and less toxic than cytoxan, adriamycin, cisplatin and cisplatin.
ABSTRACT
Purpose:Clinical research has been done to show whether continuous infusion of navelbine can increase curative effect and decrease toxicity.Methods:Patients studied were non operable NSCLC and recurrent or metastatic breast cancer. Navelbine is given through a catheter in the venae subclavia by continuous infusion for 24 hours. Regimen:NVB 10 mg/iv/day 1+NVB 10 mg/iv continuous infusion 24 h/day 1—5+DDP 40 mg/iv 2h/day 1—3+Gransetron 3 mg/iv day1,3,5 given every 21 days. Results:Among 47 patients 35 patients were NSCLC and 12 patients were breast cancer. Average age was 58.9 years. Of the NSCLC patients, 12 were squamous cell carcinoma and 23 patients were adenocarcinoma; two patients were stage Ⅱ and 19 patients stage Ⅲ, 19 patients stage Ⅳ. All of the breast cancer cases were infiltrative duct carcinoma. Three patients were stage Ⅱ and nine patients were stage Ⅳ. Of the 47 patients, 44 patients were evaluable for response and 47 patients for toxicity. Response rate of NSCLC was 57%(19 pr) and breast cancer 63% (1 cr, 6 pr). Main toxicity was granulocytopenia and vomiting. WHO Ⅲ—Ⅳ grade granulocytopenia was 40% and vomiting 6.4%. Peripheral nerves toxicity was mild and only 6.4% patients had WHO I grade peripheral sensory nerve damage. No patients had severe nerve toxicity such as enteroplegia.Conclusions:Comparison of continuous infusion Navelbine and Cisplatin with classic usage of navelbine for management of NSCLC and breast cancer showed increased response rate and decreased toxicity. Administration through catheter venae subclavia can avoid chemo phlebitis. [
ABSTRACT
Purpose:To evaluate the results of combination chemotherapy with navelbine (NVB) and cisplatin (DDP) in patients with stage Ⅲ b—IV non small cell lung cancer (NSCLC), as compared with MVP regimen. Methods:16 cases were treated with MVB+DDP, 20 cases were treated with MVP. Results:The response rate was 50.0% in patients with NVB plus DDP, 40% in those treated with MVP . The major toxic reactions in the two groups were tolerable,being myelo suppression and grstrointestinal reaction. Grade Ⅱ—Ⅳ phlebitis rate was 37.5% in patients with NVB puls DDP, 0.0% in those treated with MVP, respectively ( P 0.05). Conclusions:A higher response rate is attainable with stage Ⅲ b—IV NSCLS treated by navelbine and cisplatin with tolerable toxicity. [
ABSTRACT
Purpose: To observe the efficacy of combined chemotherapy of navelbine( NVB) and cisplatin ( DDP) plus concurrent palliative local radiotherapy in the treatment of stage M, nasopharngeal carcinoma( NPC). Methods: 21 cases of stage M, NPC received combined chemotherapy of NVB 25 mg/m2 on dl, d8 and DDP 30 mg/m2 on day 1-3. The therapy was repeated every 28 days. All patients were concurrenly treated with palliative radiotherapy for to the distant metastases areas. The radiotherapy dose varied from 15 to 60 Gy. Results: 1.The 1-, 2- and 3- year survival rates of the patients were 71.43%, 14.29% and 9.25% respectively. The median survival time ( MST) was 17 months. 2.The Cox Regression analysis showed that the effect of treatment and the liver invasion are significant prognostic factors. The survival rate is the highest in the patients with lung metastases. Conclusions: This scheme combined chemotherapy of NVB and DDP plus concurrent palliative local radiotherapy can improve the MST of the patients with stage M1 of NPC.
ABSTRACT
0.05). The major toxic reactions in the two groups was tolerable myelo-suppression. The average cost of one patient for two therapeutic cycles was (23664?384.7) and (8519.94?369.1) respectively. Escalation of 1 % of response rate costed (485.02?34.65) and (185.62?23.77) respectively. Prolongation of 1 month of median survival duration costed (2211.59?59.1) and (946.66?43.3) respectively.TTP in group GP is longer than that in group NP(P
ABSTRACT
Purpose: To evaluate the efficacy and toxicity of Navelbine( NVB) and Epirubicin ( Epi -ADM) as the neoadjuvant chemotherapy in the treatment of locally advanced breast cancer. Methods: From September 2001 to February, 2003, 76 cases, LABC patients ( II b ~ HI b ) were treated with NE chemotherapy before operation. Neoadjuvant chemotherapy regimens containing vinorelbine( N), 25 mg/m (days 1 and 8) and epirubicin( E), 60 mg/m (days 1) were administered every 3 weeks for three cycles before local treatment. The response in the primary tumor and the regional lymph nodes and the chemotherapy toxicity were observed for each patient. Results: The response in the primary tumor: clinical objective response was 84. 2% (19.7% (15/76) CR and 64. 5% (49/76) PR) , 14. 5% (11/76) SD and 1.3% (1/76) PD. Pathological complete response was found in 11 cases( 14. 5%). 9 cases (28. 1%) who have positive FNA result in the regional lymph node before chemotherapy showed negative result in the surgery specimen. The most common toxicities are leukocytopenia, nausea/vomiting and alopecia. Leucopenia grade 3-4 was reported in 54. 2% of the patients but there were no chemotherapy related toxic deaths. Conclusions: The combination of Vinorelbine and Epirubicin is a very active and well-tolerated regimen as neoadjuvant chemotherapy for the LABC.
ABSTRACT
Background and purpose:The mechanism of vinorelbine is inhibition of microtubule protein assembly and inducetion of the disaggreation of microtubles;where as docetaxed promotes the assembly of microtuble protein and inhibits normal physiological disaggreation of tubulin.We studied the curative effect and toxicity of combination of chemotherapy with navelbine(NVB) plus paclitaxel in the treatment of advanced breast cancer.Methods:Forty-two pathologically and cytologically proved cases of advanced breast cancer were treated with intravenous infusion of navelbine 25mg/m~2 on d1 and d8,paclitaxel 175mg/m~2 by 3-hour continuous infusion on d1.Interval between each cycle was 21 days and the clinical response and the toxicity were assessed after 2~4 cycles.Results:The overall response rate(RR) for the whole group of patients was 66.7% with 16.7% complete response(CR).In the first time chemotherapy patients,the RR was 72.2% with 27.2% CR;while in those with prior chemotherapy,an RR as high as 62.5% with 8.3% CR was also obtained.The 2-and 4-year survival rates was 40.5% and 21.4%,the median remission period was 8 months,the median overall survival duration was 18 months.The major side effects include leukopenia,hairloss,milieu phlebitis.Conclusions:The combination chemotherapy with navelbine and paclitaxel in treatment of advanced breast cancer is effective and the side effects could be tolerated.
ABSTRACT
0.05).CONCLUSIO_ NS:The two sets of regimen are similar in their efficacies and toxicity,both with satisfactory tolerance.
ABSTRACT
0.05).But the rates of thrombocytopenia and phlebitis in GEM group were significantly lower than NVB group.Conclusions: The short-time clinical efficacy,MST,DPT and one-year survival rate of GEM+CBP regimen were similar to those of NVB+DDP regimen,but the toxicity of GEM+CBP regimen were lower than those of NVB+DDP regimen.The GC regimen is a safe and effective regimen for old age advancde NSCLC.